January Natural Gas Futures Climb After Winter Freeze, Inventory Decline; Cash Prices Lose Luster
Natural gas futures advanced Friday following forecasts for freezing temperatures, steadily strong liquefied natural gas (LNG) levels and a bullish withdrawal from storage.
The January Nymex contract settled at $2.700/MMBtu, up 6.4 cents day/day. February rose 4.4 cents to $2.681.
NGI’s Spot Gas National Avg., meanwhile, dropped 55.0 cents to $3.010. Traders took profits and demand eased after a sprawling snowstorm that punished the Northeast, which fueled robust demand earlier in the week, dissipated on Friday.
Forecasters expected winter conditions to further ease over the weekend, with warmer-than-normal conditions spreading over most of the Lower 48 early in the Christmas holiday week. However, a widespread blast of cold was expected to arrive by Christmas Eve and last for several days, generating strong national heating demand, NatGasWeather said.
Share:
New York, NY, Dec. 17, 2020 (GLOBE NEWSWIRE) MedTech Acquisition Corporation (the Company ) announced today that it priced its upsized initial public offering of 22,000,000 units at $10.00 per unit. The units will be listed on the Nasdaq Capital Market ( Nasdaq ) and will begin trading tomorrow, Friday, December 18, 2020, under the ticker symbol MTACU . Each unit consists of one share of the Company s Class A common stock and one-third of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one share of Class A common stock at a price of $11.50 per share. Only whole warrants are exercisable and will trade. Once the securities comprising the units begin separate trading, shares of the Class A common stock and warrants are expected to be listed on Nasdaq under the symbols MTAC and MTACW, respectively.
Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Topiramate Oral Solution
Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Topiramate Oral Solution
DEER PARK, Ill., Dec. 17, 2020 Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s new drug application (NDA) for topiramate oral solution. The application has been assigned a Prescription Drug User Fee Act (PDUFA) date of August 6, 2021.
The application was submitted for three indications, including: monotherapy for treatment of partial-onset or primary general tonic-clonic seizures in patients two years age and older; adjunctive therapy for treatment of partial-onset seizures, including seizures associated with Lennox-Gastaut syndrome in patients two ye
Share this article
Share this article
REDWOOD CITY, Calif., Dec. 17, 2020 /PRNewswire/ Poshmark, Inc. (Poshmark) today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its Class A common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Poshmark has applied to list its Class A common stock on the Nasdaq Global Select Market under the ticker symbol POSH.
Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, and Barclays Capital Inc. are acting as lead book-running managers for the offering. Stifel, Nicolaus & Company, Incorporated, William Blair & Company, L.L.C, Raymond James & Associates, Inc., Cowen and Company, LLC, and JMP Securities LLC are acting as book-running managers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
LF Capital Acquisition Corp. Announces Stockholder Approval of Proposed Business Combination .
LF Capital Acquisition Corp.December 15, 2020 GMT
- Stockholders Redeem Less Than 5% of Total Public Shares Outstanding -
- Remains on Track to Complete Business Combination -
NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) LF Capital Acquisition Corp. (NASDAQ: LFAC) (“LF Capital”) announced today that LF Capital’s stockholders voted to approve the proposed business combination with Landsea Homes Incorporated (“Landsea Homes”) and certain other related transactions, pursuant to which LF Capital will acquire Landsea Homes for $344 million in total consideration, to be paid fully via 32,557,303 newly issued shares of LF Capital’s Class A common stock. In connection with the approval of the proposed business combination, LF Capital’s public stockholders have requested the redemption of